AstraZeneca PLC (AZN.LN) said Monday that the phase 3 trial of treatment drug Lynparza has met its primary endpoint.
The pharmaceutical company said the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival for patients treated with Lynparza tablets, compared to chemotherapy.
Continue Reading Below
Write to Tapan Panchal at email@example.com
(END) Dow Jones Newswires
June 05, 2017 02:32 ET (06:32 GMT)